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Abstract Members of the NTR/TNFR family mediate apopto- 
sis in many tissues, yet sequence homology has not been detected 
in their intracellular domains except for a 'death domain' in 
TNFR-1 and Fas. Here, a region of the 75 kDa neurotrophin 
receptor (NTR) has been aligned with this apoptosis-inducing 
motif. Peptides at the carboxyl terminus of each domain poten- 
tially form amphiphilic helices, one of which (in NTR) resembles 
mastoparan, a G-protein activating peptide. Molecular models of 
three death-region peptides uggest hat observed sequence simi- 
larities reflect a common structure, perhaps capable of undergo- 
ing an induced coil to helix transition. 
Key words. Neurotrophin receptor; NGF receptor: 
Molecular modeling; Apoptosis; Alpha-helix; Mastoparan 
1. Introduction 
Receptors of the NTR/TNFR family function during devel- 
opment and in adult tissues by regulating apoptotic ell death 
[1,2]. All possess extracellular domains composed of repeating 
units that fold into a characteristic structure [3,4]. However, 
except for an 'apoptosis mot i f  in TNFR- I  (55 kDa) and Fas/ 
Apo-I, neither sequence nor structural similarity has been de- 
tected in the intracellular domains of these molecules [5 7]. 
Various signaling mechanisms have been proposed for mem- 
bers of the family. Although direct substrate phosphorylation 
has been ruled out by the absence of catalytic domains, interac- 
tions with cytoplasmic signaling molecules apparently link acti- 
vated receptors to signaling cascades [8]. The established func- 
tion of the neurotrophin receptor (NTR) is to modulate the 
affinity and activity of tyrosine kinases that promote neuronal 
survival [9]. It was recently shown, however, to induce apop- 
totic cell death much like that stimulated by TNFR- I  and Fas 
[10,11]. Unlike TNFR- I  and Fas, cell death induced by NTR 
is reversed rather than caused by ligand binding. This function 
is consistent with observations that its contribution to the sur- 
vival response can best be measured at high ratios of NTR to 
co-expressed trk receptors, which also bind neurotrophins [9]. 
These reports prompted a re-examination of the intracellular 
domain of NTR for possible similarities to TNFR-1 and Fas, 
which may signal through a related mechanism, i.e. sphingo- 
myelinase activation [12 14]. 
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Here. primary sequence alignment was used to locate a death 
domain in the intracellular portion of the neurotrophin recep- 
tor. To explore structural implications of this homology, puta- 
tive structures were modeled using computer-aided molecular 
design and visualization tools. Peptides in the death-mediating 
region appear to be structurally similar to peptides that un- 
dergo a transition from coil to helix, and which activate hetero- 
trimeric G-proteins. 
2. Experimental 
2.1. Alignment and analysis o[secondary structure 
Amino acid sequences having the most complete annotation were 
obtained from databases as follows: SwissProtein; human fas antigen 
P25445, chicken NTR P18519, and rat TNFR-I P22934. PIR; 
mouse fas antigen - A46484 and human TNFR-I - A34899. GenBank; 
rat fas antigen D26112, human NTR M14764, rat NTR X05137 
and mouse TNFR-I M59378. Sequences and measurements of biolog- 
ical activity were obtained for insect venom peptides as follows: MR 
MP-X, MP-A', MP-T, Mas7, Mas9 and Masl9 [15]; MP14 and MPI5 
[16]; melittin [17]. Matrix calculations were performed by DNA Strider 
version 1.2 (Christian Marck, CEN-Saclay, France). 
Initial alignments were prepared using the algorithm of Altschul [18]. 
Multiple alignments were optimized by hand using SeqVu version 1.0.1 
(James Gardner, Garvan Institute of Medical Research, Sydney, Aus- 
tralia), based on sidechain chemistry and rational placement of gaps. 
The methods of Garnier et al. and Chou and Fasman, as modified by 
Nishikawa [19], were to evaluate the probability that a sequence could 
adopt a helical structure. Helical wheels were drawn as described by 
Schiffer and Edmundson [20]. 
2.2. Model building 
Hypothetical structures were assembled SYBYL version 6.1 (Tripos 
Associates, St. Louis, MO) on Silicon Graphics workstations. Free 
amino and carboxylate groups were left at the ends. Van der Waals 
conflicts resulting from sidechain substitutions were resolved by ro- 
tamer library and molecular mechanics functions in SYBYL. Energy 
minimization was carried out using the AMBER all-atom force field, 
a distance-dependent dielectric onstant of 4.0 R and a non-bonded 
atom cutoff of 10 A. Computer graphics were prepared with MI- 
DASPlus [21] and displayed using the conic delegate [22]. 
3. Results 
3. 1. Identification of death-domain homology in NTR 
Because widely-used alignment algorithms had not detected 
similarity in the intracellular domains of the NTR/TNFR fam- 
ily, representative s quences were evaluated with a matrix pro- 
cedure. This method looks for matches (amino acid identities) 
within a sliding window. The test is relatively insensitive to 
gaps, and can be adjusted to detect low levels of amino acid 
identity. Comparisons of NTR with TNFR- I  and Fas intracel- 
lular domains detected matches in the previously-identified 
death domain at approximately 27% sequence identity. 
Using short, matched sequences from the matrix and homol- 
ogs from additional species, residues 330 to 390 of NTR were 
0014-5793/95/$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
SSDI  0014-5793(95)01113-7 
B.S. Chapman/FEBS Letters 374 (1995) 216~20 217 
humfas 220 N~A 
musfas 216 K G 
ratfas 213 P S 
humntr 331 Q P E 
ratntr 328 Q,PE 
chintr 331 K D 
mustnfrl 342 S B 
rattnfrl 349 S B 
humtnfrl 342 S D H 
IKNDNVQD~ANQKV- -Q  N 255 
IMB DS I QD~A~QKV- -Q  C 251 
IE  HNS PQDAAIZ IOK I - -Q  C 248 
F -~HI~ICPVRA S 361 
F -~  ~ H  CPVRA S 358 
F - R SPARA D 361 
LE  MQN GRCLR~JQY- -  S A 377 
LE  LQN GRCLR~H Y - -  S A 384 
LE  L Q N GR C L R~$AIQ Y - - S T 377 
h~fas  256 NH QL  H GKKE K 
musfas 252 ~YQSHGKSD K 
ratfas 249 ~Y Q S H GK T G Q 
humntr 362 ~-  - - A T Q D S A 
ratntr 359 GAQ D S A 
chintr 362 S AK  E T V 
mustnfrl 378 ~RRRTPRHE L 
rattnfrl 385 ~RRRT PRHE R 
humtnfrl 378 ~RRRTPRRE R 
NLCTLA~K~QT I I L 290 
E CRRTLDKFQDMVQ 286 
NRC D IA~E~Q~M~W 283 
Q R A D - - - L V~IS|~IC 390 
QRAD - - -NVNSNC 387 
Q R e D - - -|~IAI~IS~|Y 390 
NLAGCLNNNLNANR 413 
NLRGCL~N~R~T~E 420 
D L L G C L~D~E~A~C 413 
Fig. 1. Multiple alignment of the death domain of NTR with those of TNFR-I and Fas. Sequence identities at the 50% level are boxed and shaded. 
Residues are numbered from the amino terminus of each receptor. 
aligned with the death regions of TNFR-I and Fas (Fig. 1). The 
alignment begins near the amino terminus of the apoptosis 
domain identified by Itoh et al. [5], and extends through the 
region probed by alanine-scanning mutagenesis of TNFR-I [6]. 
The arrangement of the domain suggests that it may have arisen 
as a duplication of approximately 38codons [23]. While NTR 
and TNFR-I share higher sequence identity (32.8%), TNFR-I 
and Fas (25.4% identity) are more closely related with respect 
to the placement of gaps and insertions. Several structural mo- 
tifs appear to be anchored by highly-conserved residues. The 
functions of Glu-369, Trp-378 and Ile-408 were tested by muta- 
tion to Ala in TNFR-I [6]. Substitution of these residues, con- 
served in the homology with NTR, blocked transmission of 
apoptotic signals. 
3.2. Potential for formation of helical structure 
Unexpected patterns of sequence gaps and amino acid iden- 
tities were investigated first by evaluating secondary-structure 
propensities in the aligned domain. Two algorithms [19] inde- 
pendently predicted alpha-helical conformations for most resi- 
dues of the nine sequences aligned in Fig. 1. For the human 
homologs of Fas, TNFR-I and NTR, regions are plotted in Fig. 
2A in which both methods predict alpha helices. Fas and 
TNFR-I show helical potential in the amino-terminal half of 
the alignment. These segments may engage in self-association 
as a consequence of activation by ligand, since deletions that 
eliminate dimerization and block signaling have been mapped 
to this region [24,25]. 
Common to all three receptors is a potential helix in the 
carboxyl-terminal half of the aligned region (Fig. 2A). This 
sequence in NTR was previously identified as a homolog of the 
wasp venom peptide, mastoparan [26]. To determine whether 
the sequences of TNFR-I and Fas might also encode masto- 
paran-like helices, peptides from the shared part of this segment 
were analyzed by display in helical-wheel p ots (Fig. 2B). The 
arrangement of sidechains strongly suggests the possibility of 
forming amphiphilic structures having one hydrophobic sur- 
face and one electrostatically-charged surface. Potential of this 
region to form an amphiphilic helix has been recognized for 
NTR and TNFR-I [26,27], but not for Fas. 
3.3. Sequences of three receptors can be modeled as stable, low- 
energy helices 
Alignment (Fig. 1) and secondary-structure pr diction (Fig. 
2) pointed to potential structural similarities among the three 
receptors. To visualize these structures, hypothetical models 
were constructed using molecular design software. Residues 
245-284 of human Fas (40 monomers) were modeled with 
alpha-helical phi and psi angles, then energy minimized using 
molecular mechanics. The AMBER force field was used to 
estimate the total energy of the model after minimization, calcu- 
lated to be -188.7 kcal/mol. Models representing human NTR 
residues 349-384 (36 monomers) and human TNFR-I residues 
367407 (41 monomers) were similarly prepared. These mini- 
mized respectively to -172.9 kcal/mol and -223.5 kcal/mol. 
A.  
hcu~fas 220 I I 290 
h ~  3~ I I 39o 
humtnfr 342 413 
S. E- K+ R+ A A D- D- A R+ E- 
~-~TK+A D-K+N I ~ A@+I  QL V ML@+D G
Fig. 2. Predictions of secondary structure in the region of homology. 
(A) Aligned sequences are represented asopen bars. Consensus seg- 
ments of alpha helix are plotted in black. (B) Helical wheel representa- 
tions of the carboxyl-terminal peptides. These show the distribution of 
amino acid sidechains a  seen looking down the axis of the helix from 
the amino-terminal end. 
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Fig. 3. Three-dimensional models of homologous regions of human Fas, NTR and TNFR-I rotated to show positions of conserved Leu and Trp 
residues. Atoms are displayed in space-filling representation with sidechains color coded as follows: polar, dark gray; charged, light gray; hydrophobic, 
black. 
Low energies achieved for the models indicate stabilization by 
extensive hydrogen bonding and excellent van der Waals inter- 
actions. The structures are completely theoretical, since neither 
solvent molecules nor dissolved ions were considered in the 
calculations. Views of these models are shown in Figs. 3 and 4. 
The three-dimensional models tart at the end of the first gap 
in NTR (see Fig. 1), which corresponds to the C-terminal 
boundary (TNFR-I Leu-367) of the postulated imerization 
motif [25]. Fig. 3 shows the prominent feature created near the 
amino terminus of the helix by sidechains of conserved Leu and 
Trp residues. The opposite sides of these structures appear 
different from each other, consistent with experimental results 
showing that mutation of Trp-378 in human TNFR-I abro- 
gated induction of cell death, but mutation of Arg-379 had no 
detectable effect [6]. 
When rotated to display a predicted helical region near its 
C-terminus, each receptor model presents a striking hydropho- 
bic face (Fig. 4). The aromatic ring of Tyr-266 in Fas appears 
to substitute for conserved leucines in NTR and TNFR-I, ori- 
enting to contribute part of a non-polar surface. A basic 
sidechain following the last conserved Leu seems to occupy a 
similar position in each structure (not labeled, coming out of 
the plane of the figure. See also 2B, where a positively-charged 
sidechain is indicated at position 11 of each helical wheel). The 
three receptor models demonstrate structural similarities, de- 
spite the low level of sequence identity. 
3.4. Potential amphiphilic helices resemble a modeled structure 
of mastoparan 
Naturally-occurring mastoparans and synthetic derivatives 
have been intensively studied as potent activators of hetero- 
trimeric G proteins [15]. These peptides reportedly assemble 
into biologically-active h lices upon interaction with phospho- 
lipid membranes or in the presence of chaotropic salts [17,28]. 
To investigate resemblances between modeled receptors and 
mastoparan, a three-dimensional representation was con- 
structed for the fourteen-residue p ptide. The mastoparan 
model relaxed to a total energy of-45.5 kcal/mol, and closely 
matched the membrane-bound structure of mastoparan-X ob- 
tained by 2D-NMR [28]. Like MP-X, modeled mastoparan 
(Fig. 5) forms an amphiphilic helix in which five aliphatic 
sidechains contribute to a non-polar surface [28]. This surface 
has several features in common with the non-polar surfaces of 
the receptor models (Fig. 4). The basic surface of mastoparan 
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Fig. 4. Models rotated to display amphiphilic helices in the lower half of each structure. Conserved hydrophobic residues are labeled. Color coding 
is identical to Fig. 3. 
likewise looks like the polar surfaces of the modeled receptors. 
For example, Lys-11 is oriented similarly to the basic sidechain 
at the bottom of each receptor's hydrophobic face. Modeling 
thus shows that the death-domain peptides could mimic the 
mastoparan structure were they to adopt a helical conforma- 
tion. 
Mastoparans, biologically-active analogs and bee-venom 
peptide (melittin) undergo a conformational transition from 
coil to helix under specific onditions [17,28]. Amino acid sub- 
stitutions in these peptides can produce molecules that neither 
stimulate G-proteins nor form helices [15,17,28]. To evaluate 
chemical similarities at critical positions, death-domain se- 
quences containing putative amphiphilic helices were aligned 
with biologically-active mastoparans and melittin (Fig. 6). The 
three apoptosis-motif peptides how strict conservation of ali- 
phatic residues at mastoparan positions 1, 6, 10 and 13. All 
other positions display substitutions comparable to at least one 
active molecule, except for the fourteenth residue, which is an 
amide or acid in the receptor peptides and aliphatic in the insect 
peptides. Chemical similarity between active mastoparans and 
segments of TNFR-I,  Fas and NTR suggests these death-do- 
main peptides may be able to undergo an induced coil to helix 
transition. 
4. Discussion 
Standard methods for detecting homology have consistently 
failed to find sequence similarities in intracellular domains of 
the NTR/TNFR family. This has led to the suggestion that 
these receptors may be chimeras [7]. An alternative possibility 
is that each member has undergone xtensive volution from 
a common ancestor in the process of adapting its structure for 
specific, non-catalytic functions. Shown here are significant 
evolutionary and structural relationships in the intracellular 
domains of the neurotrophin receptor, Fas antigen and the 55 
kDa TNF receptor. The death domain in NTR appears to be 
a robust homolog, since the percent identity with TNFR-I  is 
higher than between TNFR-I  and Fas, and because several 
residues conserved in the alignment are known to be critical for 
function [6]. 
Death-domain signaling has been difficult to unravel, owing 
to its novel structure and complex regulation. While protein 
phosphorylation may be important, experiments have not clar- 
ified whether kinases and phosphatases are primarily used for 
signaling or for regulation. In identifying a mastoparan-like 
peptide in the C-terminal half of each apoptosis domain, the 
present study expands the list of potential mechanisms. If con- 
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K4 L3 
L6 
K l l  
LO 
[13 
Mastoparan 
Fig. 5. Hypothetical model of mastoparan. This structure has a free 
carboxylate at the C-terminus, differing slightly from mastoparans and 
melittin, which are amidated. Color coding of sidechains is the same as 
in Fig. 3. 
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Fig. 6. Multiple alignment of insect venom peptides and synthetic ana- 
logs with potential amphiphilic helix residues of human Fas, TNFR-I 
and NTR. Residues chemically homologous to the mastoparan se- 
quence are boxed (e.g. aliphatic, aromatic, amidated, hydroxylated, 
basic, acidic). 
formational change from coil to helix were induced by receptor 
activation, such a peptide would act as a switch. A peptide 
representing NTR residues 367-379 has been shown by circular 
dichroism spectroscopy to assume a helical conformation in 
non-polar solvent [27]. The potentially amphiphilic peptides of 
TNFR- I  and Fas should also be tested for ability to undergo 
the coil to helix transition. NTR,  when activated, has been 
shown to stimulate Gi proteins in isolated membranes [29]. It 
may be worth exploring the pertussis-toxin sensitivity of 
TNFR- I  and Fas signaling. 
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